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Abstract 
Background 
Historically, pregnancies among women with prosthetic heart valves have been associated 
with an increased incidence of adverse outcomes.   While there have been advances in 
prosthetic heart valve design, obstetric and medical care, subsequent impact on incidence 
of adverse outcomes during pregnancy has not been quantified. 
Objectives 
To assess the risk of adverse pregnancy outcomes among women with a prosthetic heart 
valve(s) in the contemporary setting. 
Search Strategy  
Electronic literature search of Medline, The Cochrane Library, CINAHL (Cumulative Index to 
Nursing and Allied Health Literature) and Embase to find recent studies. 
Selection Criteria 
Studies of pregnant women with heart valve prostheses including trials, cohort studies and 
unselected case series. 
Data Collection and Analysis 
Absolute risks and 95% confidence intervals for pregnancy outcomes were calculated using 
either a random effects model or the logit transformation of total events and participants 
(the latter method when multiple studies had event counts of zero). 
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Main Results 
Eleven studies capturing 499 pregnancies among women with heart valve prostheses were 
eligible for inclusion.  Pooled maternal mortality rate was 0.8/100 pregnancies (95% CI 0.3-
2.1), pregnancy loss rate 32.1/100 pregnancies (95% CI 28.1-36.3) and perinatal mortality 
rate 4.7/100 births (95% CI 2.7-7.9).  
Conclusions 
Women with heart valve prostheses experienced higher rates of adverse outcomes then 
would be expected in a general obstetric population, however lower than previously 
reported.  Multidisciplinary pre-pregnancy counselling and vigilant cardiac and obstetric 
surveillance throughout the perinatal period remains warranted for these women and their 
infants. 
Keywords: Pregnancy, heart valve prosthesis, cardiovascular diseases, perinatal mortality 
 
“Tweetable” abstract 
New metaanalysis suggests reduction in maternal mortality among women with 
#heartvalveprosthesis #pregnancy 
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Introduction 
Women with underlying cardiac disease are at higher risk of adverse outcomes during 
pregnancy than the general obstetric population.  Pregnancy is a pro-coagulant state and 
contributes to an increase in haemodynamic load1-5.  As a subgroup of women with cardiac 
disease, an increased incidence of adverse outcomes has been observed among pregnancies 
in women with prosthetic heart valves.  This includes maternal mortality, miscarriage, 
thromboembolism and obstetric haemorrhage.  Infants of these women are at an increased 
risk of perinatal mortality, preterm birth, small-for-gestational-age (SGA) and congenital 
malformations6-12. 
The design of prosthetic heart valves continues to improve.  The highly thrombogenic ball-
and-cage style valves have been virtually eradicated by the newer design bi-leaflet valves, 
lowering anticoagulant requirements13.  Bioprosthetic heart valve prostheses are being 
increasingly used, as a result of developments in materials and the ability to implant using 
percutaneous techniques.  These valves avoid the need for anticoagulation during 
pregnancy13-15.  Combined with improvements in perioperative mortality and medical care, 
the outcome of these valve prosthesis advancements has been an overall improvement in 
the prognosis for heart valve prosthesis recipients, including women of reproductive age 
and children born with congenital heart disease16-19. 
There is a paucity of work exploring the outcomes of contemporary pregnancies in the 
setting of maternal heart valve prosthesis.  Recent individual studies report lower rates of 
adverse outcomes than presented in two systematic reviews, published in 2000 and 2008, 
which focused only on mechanical valves and influence of anticoagulant type 6, 12, 20, 21.  
Given the advances in prosthetic heart valve design, obstetric and medical care and 
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improvement in prognosis of contemporary heart valve prosthesis recipients, further 
investigation of the outcomes of pregnancies in the setting of maternal heart valve 
prosthesis is warranted. 
A systematic review with the primary objective of assessing the risk of an adverse outcome 
in pregnancy among women with a prosthetic heart valve(s) in the contemporary setting 
was undertaken.  The secondary outcome was to assess the absolute risk of adverse 
outcomes by prosthesis type and/or location. 
Methods 
This systematic review was performed in accordance with the previously published 
protocol22, registered with the international prospective register of systematic reviews 
(PROSPERO), number: CRD42013006187.  It was based on the guideline by the Meta-
analysis Of Observational Studies in Epidemiology (MOOSE) group (Appendix S1)23. 
Search strategy and eligibility criteria 
A systematic search of Medline, Embase, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) and The Cochrane Library was undertaken to identify relevant studies 
published between January 1995 and August 2014.  Search terms included “pregnancy” AND 
(“heart valves” “heart valve prosthesis” OR “heart valve replacement” OR “heart valve 
prosthesis implantation”).  The “explode” function was used in each case.  Searches were 
limited to studies of humans and peer-reviewed articles.  Language restrictions were not 
applied, translations were obtained as required.  Duplicates were removed.  To avoid 
overlapping populations, in cases where participants were included in more than one 
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publication, the study with the largest sample size was included.  Reference lists were 
searched for other relevant articles. 
Eligible study types were randomised controlled trials, clinical trials, cohort studies, cross-
sectional studies and unselected case series (participants not selected due to occurrence of 
an adverse event, for example valve thrombosis).  The latter were eligible because a control 
or a comparison group was not necessary to estimate the rate of adverse outcomes among 
women with valve prosthesis 
For a study to be eligible for inclusion it needed to contain at least six pregnancies in the 
setting of a maternal heart valve prosthesis, the number used in the previous systematic 
review of this topic6.  To allow assessment of contemporary outcomes, only those with 
pregnancies exclusively beyond January 1995 with less than 5% of women with ball-and-
cage style valves were eligible for inclusion.  Studies with pregnancies in women with either 
single or multiple prostheses were eligible for inclusion, as long as other criteria were met. 
Conference abstracts, posters and unpublished material were not included. 
Article titles and abstracts were evaluated by two reviewers (CR, CL) for suitability of study 
type and in regards to eligibility criteria.  Where there was disagreement or ambiguity at this 
stage, the article remained included until the full text was reviewed. 
At least two independent reviewers (CF, GF, JF, CA, SL, CL) assessed the full text of the 
remaining studies.  Where information pertinent to the other inclusion criteria was not 
contained within the article text, efforts were made to contact the listed corresponding 
author.  Where no reply was received after reasonable effort, the article was excluded.  
Consensus between the two reviewers examining the article was reached before it was 
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included.  Where consensus was not reached, a third reviewer was involved as an arbitrator.  
A log of rejected studies maintained. 
Outcomes 
The primary outcomes of interest were maternal mortality, any pregnancy loss (including 
miscarriage, termination of pregnancy and perinatal mortality or as defined by study) and 
perinatal mortality (stillbirth or neonatal mortality)24.  Stillbirth was defined as fetal death in 
utero ≥ 22 weeks gestation or as defined by the study and neonatal mortality as death in the 
first 28 days of extra-uterine life24. 
The secondary outcomes were divided into adverse maternal outcomes, mode of delivery 
and adverse birth outcomes.  Adverse maternal outcomes included any thromboembolic 
events during the pregnancy (stroke or transient ischaemic event (TIA), valve thrombosis or 
other), any obstetric haemorrhage (whether antenatal or postpartum), any cardiovascular 
compromise (as defined by study), valve deterioration (bioprosthetic valves only, as defined 
by study), any new maternal arrhythmia, infective endocarditis, myocardial infarction and 
pregnancy hypertension including gestational hypertension, pre-eclampsia and eclampsia.  
Mode of delivery was either cesarean section or vaginal birth.  Adverse birth outcomes 
included preterm birth (delivery <37 weeks of gestation), small for gestational age (SGA) 
(less than tenth birth weight percentile for sex and gestational age), low birth weight (LBW) 
(birth weight <2 500 grams), infant admission to Neonatal Intensive Care Unit (NICU) and 
congenital malformation. 
Data extraction 
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Data extraction from each identified article was undertaken by two independent reviewers 
(CR, GF, JF, CA, SL, CL) using a uniform template.  Discrepancies were resolved by discussion, 
and where applicable, arbitration by a third reviewer.  Information extracted from each 
study included study characteristics (authors, year of publication, study design, location, 
time period of included pregnancies), population characteristics (number of participants, 
number of pregnancies, maternal age, parity), heart valve characteristics (number of 
mechanical valves, number of bioprosthetic valves, implanted valve type, implanted valve 
location, anticoagulation regimen) and outcomes (frequency of primary and secondary 
outcomes as outlined above). 
Analysis 
The absolute risk, or event rate, of maternal mortality and any pregnancy loss was 
expressed as the proportion of the total number of pregnancies in women with heart valve 
prostheses.  The absolute risk, or event rate, of perinatal death and secondary adverse birth 
outcomes was expressed as a proportion of pregnancies beyond 22 weeks gestation or 500 
grams or resulting in a live birth24 in women with heart valve prostheses.  If insufficient 
details to differentiate between early pregnancy loss and fetal death >22 weeks were 
provided, the study was excluded from analysis for those outcomes relying on this 
information for the denominator.  For consistency across outcomes and with published 
studies rates were reported per 100 pregnancies or births, as appropriate. 
Pre-specified subgroup analyses of primary and secondary outcome risk, or event rate, by 
valve location and valve type were undertaken if the outcome was reported by at least two 
studies, each with at least six pregnancies in the subgroup22.  For these analyses, women 
with more than one valve prosthesis type were excluded.  Pooled event rates were 
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preferentially calculated using a random effects model, with variances calculated using a 
logit conversion in Comprehensive Meta Analysis (Version 2.0) software (Biostat, 
Englewood, NJ, USA).  Graphical summaries of individual study estimates and overall 
estimates were also produced.  The possible effect of sampling error was assessed using 
95% confidence intervals (CI) around risk estimates.  When the event count in any given 
study was zero, the zero was replaced with a value of 0.001.  When more than 10% of the 
total population contributing to a particular meta analysis came from studies with an event 
rate of zero, the logit transformation of the total events and total participants was used to 
calculate the pooled event rate and 95% CI.  This avoided the overweighting of studies with 
non-zero event rates if the random effects method was used.  To compare rates 
(proportions) between subgroups (i.e. mechanical versus bioprosthetic valves) a standard 
chi-square test of two proportions was performed to identify significant differences. 
Where applicable, heterogeneity of rates within a meta-analysis was assessed with the I2 
statistic.  Study heterogeneity was explored by the study design, the year of publication, the 
time period within which pregnancies occur and population characteristics (ethnicity, age 
range, aetiology of underlying disease, type and location of heart valve prosthesis, 
anticoagulant regimen).  
To assess the risk of bias in non-randomised studies, the Newcastle–Ottawa scale (NOS) for 
assessing the quality of non-randomised studies in meta-analyses was used 25.  The NOS for 
case-control and cohort studies was adapted to meet the specific needs of this systematic 
review; with a modified scale for use in case series22.  Using this scale, studies were awarded 
a star based on points for items related to the selection of study groups, the comparability 
of groups and the ascertainment of outcome of interest.  If a control group was present, a 
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maximum of nine stars could be achieved.  Case series (no control group) were eligible for a 
maximum of six stars.  Scoring was undertaken by two independent reviewers (SL, CL), with 
a third reviewer (CR) as an arbitrator if disagreement occurred. 
The strength of evidence was assessed with respect to the study designs, the 
methodological quality of individual studies, consistency of results across studies and for 
studies with a comparison group, the strength of associations.  Given that most studies were 
uncontrolled case series, the strength of evidence was assessed primarily by the width of 
the confidence interval around pooled outcome rates.  Consistency of effect was 
demonstrated visually in the plots and via the I2 estimate26.  For analyses where multiple 
studies with zero event rates dictated use of the logit transformation for the pooled result 
rather than a random effects analysis, no I2 estimate was calculated. 
Results 
The literature search identified 1402 original articles (Figure 1).  After initial screening, 1 364 
records were excluded.  The full-text of the remaining 38 articles was reviewed to assess 
eligibility.  A further 27 articles were excluded (Appendix S2), leaving 11 studies deemed 
suitable for inclusion.  Search of reference lists of relevant systematic reviews and included 
studies did not yield any further relevant articles.  
Of the 11 included studies20, 27-35, four were prospective unselected case series, three from 
single centres29, 34, 35 and one multiple centre27.  There were seven retrospective studies, 
two population-based cohort studies20, 21, two multicentre unselected case series 28, 32, 33 and 
three single centre unselected case series28, 30, 31 (Table 1).  Ten studies captured a total of 
305 women undertaking 392 pregnancies.  For the remaining study, only the number of 
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pregnancies could be identified20.  In total 499 pregnancies to women with a heart valve 
prosthesis were eligible for inclusion in this review. 
The studies were published from 2007 to 2014 and included pregnancies occurring from 
1997 to 2012 with both mechanical and bioprosthetic heart valves.  Anticoagulant regimens 
used in the setting of mechanical heart valve prostheses included low molecular weight 
heparin and oral anticoagulation (Table 1). The aetiology of underlying heart disease was 
both congenital and acquired. 
Assessment of the methodological quality of the included studies 
Using the modified Newcastle-Ottawa scale22, the two cohort studies were awarded seven 
and eight stars respectively, one study20 controlled for only  one factor, maternal age, the 
other did not control for any factors in the comparison group 21.  Of the remaining studies 
without control groups, one study32 was awarded the maximum six stars, seven awarded 
five stars27-29, 31, 33-35 and one awarded three stars30.  All included studies were assessed as 
including an adequate representation of cases, with appropriate follow-up.  The most 
common reason for failure to be allocated a star was non-blinded assessment of outcomes 
(Table 1). 
Outcomes 
Meta-analysis of event rates was undertaken for the 11 included studies given the similar 
pregnancy cohorts and acceptable methodological quality of the studies.  Unadjusted pooled 
event rates and 95% confidence intervals (CI) are reported in Table 2.  All included studies 
reported information on maternal mortality and any pregnancy loss.  Eight of the eleven 
studies allowed identification of perinatal mortality20, 21, 27-29, 31, 32, 34, three studies had 
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insufficient details to differentiate early pregnancy loss from fetal death at greater than 22 
weeks30, 33, 35.  No studies reported the incidence of infective endocarditis or neonatal 
admissions to the intensive care unit. 
There were four maternal deaths in 499 pregnancies, giving a maternal mortality rate of 0.8 
per 100 pregnancies (95% CI 0.3-2.1) (Figure 2).  Of the maternal deaths, one was due to 
heart failure in the antenatal period20, one during delivery35 and two due to haemorrhage. 
Of those due to haemorrhage, one was due to an intracerebral bleed in the setting of an 
elevated International Normalised Ratio (INR) of 631 and the other due to an obstetric 
haemorrhage on day three following caesarean section20.  Pregnancy loss occurred in 160 of 
the 499 pregnancies, giving a pregnancy loss rate of 32.1 per 100 pregnancies (95% CI 28.1-
36.3) (Figure 3).  There were 14 perinatal deaths in 279 births, giving a perinatal mortality 
rate of 4.7 per 100 births (95% CI 2.7-7.9) (Figure 4).  Other adverse maternal outcomes are 
outlined in Table 2. 
For the pre-specified subgroup analysis there were 256 pregnancies where the maternal 
heart valve prosthesis was known to be mechanical. Among these pregnancies there were 2 
maternal deaths, giving a maternal mortality rate of 0.8 deaths per 100 pregnancies (95% CI 
0.2-3.1).  There were 8 perinatal deaths in 124 births, giving a perinatal mortality rate of 9.9 
per 100 births (95% CI 5.7-16.7).  The rate of thromboembolism was 16.2 per 100 
pregnancies (95% CI 11.6-22.2).  Among women the 59 women with bioprosthetic valves 
there were no maternal deaths, giving a rate of 0 per 100 pregnancies (95% CI not 
calculable).  There were 2 perinatal deaths in 47 births giving a perinatal mortality rate of 5.3 
deaths per 100 births (95% CI 1.3-19.1).  The rate of thromboembolism was 0.8 per 100 
pregnancies (95% CI 0.1-12.0).  The remainder of the adverse events by valve type are 
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summarised in Table 3 below.  When undertaking the Chi-square analysis, the only 
statistically significant difference between the two valve types was in the rate of 
thromboembolism (32 events in 256 pregnancies in mechanical group versus no events in 59 
pregnancies in bioprosthetic group, two tailed p-value <0.01). 
Subgroup analysis by prosthetic valve location (mitral or aortic) was undertaken (Table 4).  In 
the aortic valve group the maternal mortality rate was 0.8 deaths per 100 pregnancies (95% 
CI 0.0-11.3).  The rate of thromboembolism was 15.3 per 100 pregnancies (95% CI 7 0.3-
29.4).  The maternal mortality rate in the mitral valve group was 1.3 deaths per 100 
pregnancies (95% CI 0.2-8.4).  The rate of thromboembolism in the mitral valve group was 
11.4 per 100 pregnancies (95% CI 0.6-20.5).  
Discussion 
Main Findings 
This systematic review quantifies the outcomes of contemporary pregnancies among 
women with prosthetic heart valves, including bioprosthetic valves.  The risk of maternal 
and infant adverse outcomes during and following pregnancy remains significant. 
The maternal mortality rates for any prosthesis (0.8/100 pregnancies, 95% CI 0.3-2.1), and 
for mechanical heart valve prostheses alone (0.8/100 pregnancies (95% CI 0.2-3.1), were 
lower than the previously reported 2.9/100 (95% CI 1.9-4.2) by Chan et al. including only 
pregnancies in the setting of mechanical valves in their earlier systematic review6.  The 
causes of maternal mortality appear to have changed; in the previous systematic review 17 
of the 25 maternal deaths were attributable to valve thrombosis and related complications 6 
compared to no deaths due to valve thrombosis in the current review, potentially reflecting 
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improvement in mechanical prosthesis design and modified anticoagulation regimens and 
monitoring.  The rate of maternal mortality in women with a prosthetic heart valve 
(800/100 000) was higher than overall maternal mortality rates in the included countries 
which ranged from 4/100 000 (Italy) to 140/100 000 (South Africa)36. 
The rate of pregnancy loss in the setting of maternal heart valve prosthesis remains high 
(32/100 pregnancies), and is potentially underreported in the retrospective studies.  The 
two largest studies reported vastly different rates of pregnancy loss rates, 23/136 (17%) and 
67/107 (63%)20, 21.  Both were retrospective population-based studies that scored favourably 
when assessed for risk of bias (Table 1).  However, methods varied; Sillesen et al.20 
attempted to contact women to identify spontaneous first trimester abortions.  The 
Australian study relied on routinely collected data that only included miscarriages or 
terminations of pregnancy requiring hospital admission21.  In the previous systematic 
review, Chan et al. reported a similar rate of any fetal loss, 31/100 pregnancies (356/1 145), 
from both prospective and retrospective studies6. 
The perinatal mortality rate, 4.7 per 100 births (95% CI 9.3-17.8) was in keeping with the 
overall global perinatal mortality rate, 4.7/10024.  Although, of the 8 studies reporting this 
outcome, 5 of the smaller studies reported no perinatal deaths27-29, 32, 34.  Both the highest31 
and lowest 34 rates of perinatal mortality were reported from South African studies.  
Differing study populations, designs and time periods are all likely contributors to this 
observed difference.  The number of perinatal deaths in the Australian study (2 deaths in 
115 births) 21 and Danish study (3 deaths in 43 births)20 were significantly higher than the 
overall perinatal mortality rate for the regions to which these countries belonged24, 
Prosthetic heart valves in pregnancy: A systematic review 
15 
 
suggesting perinatal mortality remains a risk for pregnancies in women with heart valve 
prostheses.  
Strengths and Limitations 
Strengths of this review include the contemporary population, reflecting present day 
management with the exclusion of older-style valve prostheses.   Bias was reduced by 
including articles independent of language and removing duplicate study populations.  
Unpublished studies were excluded.  Sources of bias included lack of blinding in outcome 
assessment and the possible selective nature or incomplete reporting of outcomes in 
individual studies.  There was also a lack of methodologically superior study types.  There 
was a moderate degree of heterogeneity in the analyses which could be assessed using the 
I2 estimate26.   Although the analysis by valve type and position provides information for 
counselling, the relatively small number of pregnancies available for subgroup evaluation by 
valve type and valve location limited the conclusions that could be drawn from these 
analyses. 
Interpretation 
From this review, the ongoing need for multidisciplinary pre-pregnancy counselling and 
vigilant cardiac and obstetric surveillance throughout the perinatal period is clear.  This is 
particularly evidenced by the increased risk of maternal and perinatal mortality, fetal loss 
and other adverse events during pregnancy in women with heart valve prostheses.  In the 
future there may be potential to specifically tailor counselling and monitoring to valve type 
and location, as explored below, in light of the findings of this review and other evidence.  
Ongoing work in this area is needed. 
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Previous studies have reported varying rates of thromboembolic events by anticoagulation 
regimen during pregnancy among women with mechanical heart valve prostheses.  This 
review found the thromboembolic event rate to be 13.3/100 pregnancies (95% CI 9.3-17.8), 
higher when including only women with mechanical valves and lower among women with 
bioprosthetic valves.  A variety of anticoagulation regimens were included in the mechanical 
valve group; oral anticoagulation with conventional and low-dose protocols, low molecular 
weight heparin and no anticoagulation.  Subgroup analysis by anticoagulation type has been 
addressed in detail by two earlier systematic reviews6, 12 reporting rates of 
thromboembolism from 3.9/100 (oral anticoagulation) to 33.3/100 (heparin)6. 
Few studies reported outcomes for women with bioprosthetic heart valves21, 28.  Pregnancy 
has been purported to be safer in the presence of bioprosthetic as opposed to mechanical 
valves, largely due lack of routine anticoagulation.  In this review, bioprosthetic valves were 
associated with lower rates of thromboembolic events than mechanical valves. This is not 
surprising given the lack of a thrombogenic substrate in bioprosthetic valves.  Rates of other 
outcomes were generally lower for bioprosthetic valves although no other comparisons 
achieved statistical significance, partly due to smaller sample size in the bioprosthetic group.  
Further work is needed to clarify the contemporary outcomes of women undertaking 
pregnancy with a bioprosthetic heart valve, particularly given the recommendation that this 
valve type be considered for women wishing to have children14, 37, 38.  
Mitral valve prostheses have been previously associated with a higher incidence of mortality 
and complications compared to aortic39-41.  In this review the rate of thromboembolic 
events was similar for women with an aortic compared to a mitral valve prosthesis 
(15.3/100 and 11.4/100 respectively).  Further research on the impact of valve location on 
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pregnancy outcome among a larger pregnancy cohort would allow tailored counselling and 
management of valve-type for location specific subgroups. 
The observed rate of obstetric haemorrhagic events (7.1/100 pregnancies), remained higher 
than current global population estimates of post partum haemorrhage (6.0/100)42, 
potentially due to the impact of anticoagulation required for women with mechanical 
valves.  The previous systematic review reported “major bleeding events” only, occurring in 
2.5% of pregnancies6.  Caregivers of pregnant women with prosthetic heart valves need to 
remain vigilant in early recognition of significant bleeding throughout the perinatal period. 
The relationship between maternal cardiac disease and adverse neonatal outcomes is not 
fully understood; there is a higher incidence of prematurity (both iatrogenic and 
spontaneous), SGA and congenital malformation reported in other studies and this review43-
45.  As heart valve replacements occur for both acquired and congenital cardiac disease, the 
finding of higher incidence of congenital heart disease in infants is not surprising given the 
genetic basis of some of these conditions46.  In accordance with guidelines, fetal 
echocardiography is warranted in these high risk women37. 
Conclusion 
Pregnancies in the contemporary setting undertaken by women with prosthetic heart valves 
remain at an increased risk of adverse outcomes, including maternal mortality, pregnancy 
loss and perinatal mortality. The risk of maternal mortality is lower than previously 
reported.  While deaths due to valve thrombosis appears to have declined, women with 
mechanical heart valves remain at increased risk of thromboembolic events.  Amongst 
infants, higher rates of prematurity, SGA and congenital malformations, including not only 
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the historically-reported warfarin embryopathy but also congenital heart disease, were 
seen.  Multidisciplinary pre-pregnancy counselling as well as vigilant cardiac and obstetric 
surveillance throughout the perinatal period remains warranted for these women and their 
infants. 
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Table 1: Characteristic of included studies 
Study, 
year of publication, 
reference (country) 
Type Participants Exposure Outcome Risk of bias* 
Abildgaard, 2009, (26) 
(Norway) 
Prospective, 
case series, 
multicentre 
11 women (12 
pregnancies) with 
PHV managed in 
Norway 1997-
2008. 
Mechanical PHV 
inserted prior to 
pregnancy with 
LMWH used during. 
No maternal or 
perinatal mortality 
or any pregnancy 
loss reported. 
5 stars, assessment of 
outcome non-blinded 
Basude, 2014, (27) 
(United Kingdom) 
Retrospective 
case series, 
single centre 
16 women (32 
pregnancies) with 
PHV managed 
1998-2012. 
Aortic PHV only 
(except in setting of 
Ross procedure) 
inserted prior to 
pregnancy. 
1 maternal death, 
17 pregnancy 
losses, 1 perinatal 
death. 
5 stars, assessment of 
outcome non-blinded 
 
De Santo, 2012, (28) 
(Italy)  
Prospective 
case series, 
single centre 
20 women (20 
pregnancies) with 
PHV managed 
2000-2010 
Mechanical PHV 
inserted prior to 
pregnancy with low 
dose OAC during. 
No maternal or 
perinatal mortality 
or any pregnancy 
loss reported. 
5 stars, assessment of 
outcome non-blinded 
Lawley, 2014, (21) 
(Australia) 
Retrospective 
cohort study, 
population 
based 
87 women (136 
pregnancies) with 
PHV managed 
2000-2011 
PHV inserted prior 
to pregnancy 
No maternal 
mortality, 23 
pregnancy losses, 2 
perinatal deaths 
7 stars, comparison 
group with unadjusted 
risk 
Lee, 2007, (29) 
(Korea) 
Retrospective 
case series, 
single centre 
25 women (31 
pregnancies) with 
PHV managed 
1997-2005 
Mechanical PHV 
inserted prior to 
pregnancy. 
No maternal death, 
6 pregnancy losses, 
perinatal mortality 
unable to be 
ascertained. 
3 stars, exclusion 
criteria not stated, no 
description of 
ascertainment of 
exposure, assessment of 
outcome non-blinded 
Mazibuko, 2012, (30) 
(South Africa) 
Retrospective 
case series, 
single centre 
61 women (61 
pregnancies) with 
PHV managed 
2005-2009 
PHV inserted prior 
to pregnancy. 
1 maternal death, 
18 pregnancy 
losses, 8 perinatal 
deaths (2 neonatal 
deaths, 6 stillbirths) 
5 stars, assessment of 
outcome non-blinded 
Nelson-Piercy, 2013, 
(31) (United Kingdom) 
Retrospective 
case series, 
multicentre 
9 women (9 
pregnancies) with 
PHV managed 
1998-2006 
Mechanical PHV 
inserted prior to 
pregnancy with 
Tinzaparin during. 
No maternal or 
perinatal mortality 
or any pregnancy 
loss reported. 
6 stars 
Popelova, 2012, (32) 
(Czech Republic) 
Retrospective 
case series, 
multicentre 
14 women (23 
pregnancies) with 
PHV managed 
2006-2010 
Mechanical PHV 
inserted prior to 
pregnancy. 
No maternal death, 
6 pregnancy losses, 
perinatal mortality 
unable to be 
ascertained. 
5 stars, assessment of 
outcome non-blinded 
Saeed, 2011, (33) 
(South Africa) 
Prospective 
case series, 
single centre 
15 women (15 
pregnancies) with 
PHV managed 
2007-2009 
Mechanical PHV 
inserted prior to 
pregnancy with 
Enoxaparin during. 
No maternal or 
perinatal mortality 
or any pregnancy 
loss reported. 
5 stars, assessment of 
outcome non-blinded 
Samiei, 2012, (34) 
(Iran) 
Prospective 
case series, 
single centre 
47 women (53 
pregnancies) with 
PHV managed 
1999-2009 
Mechanical mitral 
PHV inserted prior 
to pregnancy. 
1 maternal death, 
21 pregnancy 
losses, perinatal 
mortality unable to 
be ascertained. 
5 stars, assessment of 
outcome non-blinded 
Sillesen, 2011, (20) 
(Denmark) 
Retrospective 
cohort study, 
population 
based 
79 women (155 
pregnancies, 107 
of which were 
managed 1997-
2007 
PHV inserted prior 
to pregnancy 
2 maternal deaths, 
66 pregnancy 
losses, 3 perinatal 
deaths (2 stillbirths, 
1 neonatal death) 
8 stars, comparison 
group controlled for 
only one factor 
PHV prosthetic heart valve, LMWH low molecular weight heparin, OAC oral anticoagulant 
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*Risk of bias assessed using adapted Newcastle–Ottawa scale (NOS) for assessing the quality 
of non-randomised studies in meta-analyses (22, 24), case series eligible for maximum of six 
stars and cohort studies for a maximum of nine stars
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Table 2: Pooled event rates of outcomes in pregnancy 1 
Outcomes* Number of studies (references)† Number of events 
/sample size 
Pooled event rate per 100 (95% 
Confidence interval) 
I2 estimate 
(%) 
Maternal mortality† 11 (20, 21, 26-34) 4/499 0.8 (0.3-2.1) NC 
Any pregnancy loss 
including neonatal 
death† 
11 (20, 21, 26-34) 160/499 32.1 (28.1-36.3) NC 
Perinatal mortality† 8 (20, 21, 26-28, 30, 31, 33) 13/279 4.7 (2.7-7.9) NC 
Thromboembolic event 10 (20, 21, 26-34) 34/499 13.3 (9.5-18.2) 72.2 
Obstetric haemorrhage† 8 (20, 21, 26-28, 30, 31, 33) 21/295 7.1 (4.7-10.7) NC 
Cardiovascular 
compromise 
5 (20, 21, 26, 27, 34) 9/302 4.2 (2.2-8.0) 37.6 
Pregnancy-associated 
hypertension 
3 (21, 26, 27) 20/143 14.1 (9.3-20.9) 0.0 
Caesarean delivery 4 (21, 26, 30, 31) 98/185 52.2 (44.8-59.6) 74.8 
Vaginal delivery 4 (21, 26, 30, 31) 87/185 47.8 (40.4-52.2) 74.8 
Preterm birth 5 (20, 21, 26, 27, 33) 50/201 26.5 (20.5-33.5) 76.7 
SGA 2 (20, 21)  27/274 16.4 (11.5-22.9) 38.3 
Congenital malformation† 4 (20, 26, 28, 30) 11/124 8.9 (5.0-15.3) NC 
SGA small-for-gestational-age, NC not calculated due to multiple trials with zero events. 2 
*As defined in objectives.  Outcome only included if reported in more than 1 study. 3 
† Logit transform performed as greater than 10% of the population contributing in analysis had zero events 4 
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Table 3: Pooled estimates rates of outcomes in pregnancy by valve type 1 
Outcomes* Number of studies 
(references) 
Number of events 
/sample size 
Pooled event rate per 100 (95% 
Confidence interval) 
I2 estimate (%) 
Mechanical valve prosthesis only 
Maternal mortality† 10 (21, 26-34) 2/256 0.8 (0.2-3.1) NC 
Any pregnancy loss including 
neonatal death† 
10 (21, 26-34) 69/256 27.0 (21.9-32.7) NC 
Perinatal mortality† 7 (21, 26-28, 30, 31, 33) 12/121 9.9 (5.7-16.7) NC 
Thromboembolic event 9 (21, 26-34) 32/236 16.7 (11.9-22.8) 49.1 
Obstetric haemorrhage† 7 (21, 26-28, 30, 31, 33) 14/131 10.7 (6.4-17.2) NC 
Cardiovascular compromise† 5 (21, 26, 27, 33, 34) 6/117 5.1 (2.3-10.9) NC 
Caesarean delivery 5 (21, 26, 28, 30, 31) 73/99 69.7 (58.8-78.8) 60.2 
Vaginal delivery† 5 (21, 26, 28, 30, 31) 26/99 26.3 (18.5-35.8) NC 
Preterm birth 4 (21, 26, 27, 33) 12/48 26.1 (15.4-40.8) 0.0 
New arrhythmia† 2 (21, 30) 8/79 10.1 (5.1-19.0) NC 
Congenital malformation† 3 (26, 28, 30) 5/76 6.6 (2.8-14.9) NC 
Bioprosthetic valve prosthesis only 
Maternal mortality† 2 (21, 27) 0/59 0.0 (Not calculable‡) NC 
Any pregnancy loss including 2 (21, 27) 14/59 25.5 (15.4-39.2) 81.3 
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neonatal death 
Perinatal mortality 2 (21, 27) 2/47 5.3 (1.3-19.1) 0.0 
Thromboembolic event† 2 (21, 27) 0/59 0.8 (0.1-12.0) NC 
Obstetric haemorrhage† 2 (21, 27) 7/47 14.9 (7.3-28.1) NC 
Cardiovascular compromise† 2 (21, 27) 3/59 5.1 (1.6-14.6) NC 
Preterm birth† 2 (21, 27) 6/47 12.8(5.8-25.6) NC 
SGA 2 (21, 27) 7/47 15.0 (7.3-28.3) 0.0 
SGA small-for-gestational-age, NC not calculated due to multiple trials with zero events 1 
* As defined in objectives.  Outcome only included if reported in more than 1 study. 2 
† Logit transform performed as greater than 10% of the population contributing in analysis had zero events  3 
‡ Not calculable due to event rate of zero 4 
  5 
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Table 4: Pooled event rates of outcomes by valve location 1 
Outcomes* Number of studies (references) Number of events 
/sample size 
Pooled event rate per 
100 (95% Confidence 
interval) 
I2 estimate 
(%) 
Aortic valve prosthesis 
Maternal mortality† 4 (26-28, 32) 0/63 0.8 (0.0-11.3) NC 
Any pregnancy loss including neonatal 
death† 
4 (26-28, 32) 15/63 23.8 (14.9- 35.8) NC 
Thromboembolic event 4 (26-28, 32) 7/63 15.3 (7.3-29.4) 43.9 
Obstetric haemorrhage† 3 (26-28) 2/50 4.0 (1.0-14.6) NC 
Cardiovascular compromise† 2 (26, 27) 1/32 3.1 (0.4-19.1) NC 
Mitral valve prosthesis 
Maternal mortality† 3 (27, 29, 30, 33) 1/79 1.3 (0.2-8.4) NC 
Thromboembolic event† 3 (27, 29, 30, 33) 9/79 11.4 (6.0-20.5) NC 
NC not calculated due to multiple trials with zero events 2 
* As defined in objectives.  Outcome only included if reported in more than 1 study. 3 
† Logit transform performed as greater than 10% of the population contributing in analysis had zero events 4 
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Figure 1: Process of selection of the studies for the systematic review 1 
 2 
* Exclusion reasons: Including pregnancies prior to 1995 (n=12), ≥5% ball-and-cage 3 
valves (n=7), duplicate study population (n=3), authors unable to be contacted after 4 
reasonable attempts to clarify information relevant to inclusion criteria (n=4), no 5 
primary outcomes of interest reported (n=1), see Appendix 1. 6 
 7 
  8 
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Figure 2: Rate ratio for maternal mortality from all 11 included studies 1 
Study  Number of 
maternal 
deaths/number 
of pregnancies  
 
Rate per 100 
pregnancies (95% CI)* 
 2 
CI confidence interval 3 
*When zero events in study 95% confidence interval not calculated, represented by dashed 4 
line in forest plot 5 
  6 
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Figure 3: Rate ratio for any pregnancy loss from all 11 included studies 1 
Study  Number of 
maternal 
deaths/number 
of pregnancies  
Rate per 100 
pregnancies 
(95% CI)* 
 2 
CI confidence interval 3 
*When zero events in study 95% confidence interval not calculated, represented by dashed 4 
line in forest plot 5 
  6 
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Figure 4: Rate ratio for perinatal mortality from eight eligible studies 1 
Study  Number of 
perinatal 
deaths/number of 
included births*  
Rate per 100 
pregnancies 
(95% CI)† 
 2 
CI confidence interval 3 
* Births: Birth >22 weeks gestational age or 500 grams or live birth (23) 4 
† When zero events in study 95% confidence interval not calculated, represented by dashed 5 
line in forest plot 6 
  7 
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Appendix S1: Reporting Checklist from Meta-analysis Of Observational Studies in 1 
Epidemiology (MOOSE) group 1 2 
Requirement  Page 
Reporting of background  
Problem definition 5 
Hypothesis statement 5 
Description of study outcome(s) 7 
Type of exposure or intervention used 6 
Type of study designs used 6 
Study population 6 
Reporting of search strategy 
Qualifications of searchers (eg, librarians and  investigators) 1 
Search strategy, including time period included in the synthesis and keywords 6 
Effort to include all available studies, including contact with authors 6 
Databases and registries searched 5 
Search software used, name and version, including special features used (eg, explosion) 5 
Use of hand searching (eg, reference lists of obtained articles) 5 
List of citations located and those excluded, including justification App 2* 
Method of addressing articles published in languages other than English 5 
Method of handling abstracts and unpublished studies 6 
Description of any contact with authors 6 
Reporting of methods  
Description of relevance or appropriateness of studies assembled for assessing the hypothesis to 
be tested 
6 
Rationale for the selection and coding of data (eg, sound clinical principles or convenience) 7-8 
Documentation of how data were classified and coded (eg, multiple raters, blinding, and 
interrater reliability) 
7-8 
Assessment of confounding (eg, comparability of cases and controls in studies where appropriate) 9 
Assessment of study quality, including blinding of quality assessors; stratification or regression on 
possible predictors of study results 
9 
Assessment of heterogeneity 9 
Description of statistical methods (eg, complete description of fixed or random effects models, 
justification of whether the chosen models account for predictors of study results, dose-
response models, or cumulative meta-analysis) in sufficient detail to be replicated 
8-9 
Provision of appropriate tables and graphics Tables 1-4 
Figures 1-4 
Reporting of results 
Graphic summarizing individual study estimates and overall estimate Figures 2-4 
Table giving descriptive information for each study included Table 1 
Results of sensitivity testing (eg, subgroup analysis) NA 
Indication of statistical uncertainty of findings Table 2-4 
Reporting of discussion 
Quantitative assessment of bias (eg, publication bias) 16-17 
Justification of exclusion (eg, exclusion of non-English-language citations) 16-17 
Assessment of quality of included studies Table 1 
Reporting of conclusions 
Consideration of alternative explanations for observed results 13-16 
Generalization of the conclusions (ie, appropriate for the data presented and within the domain 
of the literature review) 
16 
Guidelines for future research 15-16 
Disclosure of funding source 16 
*Appendix 2 3 
1. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of 4 
observational studies in epidemiology: a proposal for reporting. Meta-analysis Of 5 
Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000 Apr 19;283(15):2008-6 
12. 7 
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 1 
Appendix S2: References of studies excluded after screening of full text 2 
 3 
Exclusion reasons 4 
1: Including pregnancies prior to 1995 (n=12) 5 
2: ≥5% ball-and-cage valves (n=7) 6 
3: Duplicate study population (n=3) 7 
4: Authors unable to be contacted after reasonable attempts to clarify information relevant to 8 
inclusion criteria (n=4) 9 
5: No primary outcomes of interest reported (n=1) 10 
 11 
Study Reason 
Al-Lawati AA, Venkitraman M, Al-Delaime T, Valliathu J. Pregnancy and 
mechanical heart valves replacement; dilemma of anticoagulation. European 
Journal of Cardio-Thoracic Surgery. 2002; 22:223-227. 
1 
Ashour ZA, Shawky HA, Hassan Hussein M. Outcome of pregnancy in women with 
mechanical valves. Texas Heart Institute Journal. 2000; 27:240-245. 
1 
Avila WS, Rossi EG, Grinberg M, Ramires JA. Influence of pregnancy after 
bioprosthetic valve replacement in young women: a prospective five-year study. 
Journal of Heart Valve Disease. 2002; 11:864-869. 
1, 5 
Ayhan A, Yucel A, Bildirici I, Dogan R. Feto-maternal morbidity and mortality after 
cardiac valve replacement. Acta Obstetricia et Gynecologica Scandinavica. 2001; 
80:713-718. 
1 
Basude S, Hein C, Curtis SL, Clark A, Trinder J. Low-molecular-weight heparin or 
warfarin for anticoagulation in pregnant women with mechanical heart valves: 
what are the risks? A retrospective observational study. BJOG: An International 
Journal of Obstetrics & Gynaecology. 2012; 119:1008-1013; discussion 1012-
1003. 
3 
Dong L, Shi Y, Tian Z. [The follow-up of 12 pregnant women with anticoagulation 
therapy after mechanical heart valve replacement]. Chung-Hua Fu Chan Ko Tsa 
Chih [Chinese Journal of Obstetrics & Gynecology]. 2001; 36:465-467. 
1 
Geelani MA, Singh S, Verma A, Nagesh A, Betigeri V, Nigam M. Anticoagulation in 
patients with mechanical valves during pregnancy. Asian Cardiovascular & 
Thoracic Annals. 2005; 13:30-33. 
1, 2 
Hassouna A, Allam H. Oral anticoagulation therapy during pregnancy in patients 
with mechanical mitral valves: a prospective study. Cardiovascular Surgery. 2001; 
9:478-481. 
1 
Izaguirre R, De La Pena A, Ramirez A, Cortina E, Huerta M, Salazar E. Anti-Xa 
2 
Prosthetic heart valves in pregnancy: A systematic review 
39 
 
activity with low-molecular-weight heparin, enoxaparin, during pregnancy in 
women with mechanical heart valves. Proceedings of the Western Pharmacology 
Society. 2002; 45:127-128. 
Kashfi F, Samiei N, Khamoushi AJ, Hosseini S, Ghavidel AA, Taheripanah R. 
Pregnancy after mechanical mitral valve replacement. Iranian Red Crescent 
Medical Journal. 2012; 14. 
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